We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.



Our multitarget stool DNA test (Cologuard) was developed using the principles of biology, chemistry and molecular biology. As a result, it is a powerful combination of technologies packaged into one convenient and highly effective precancer and cancer screening test.

In creating a stool DNA-based test, we sought to incorporate the most discriminating and informative biomarkers to ensure the highest possible sensitivity in detecting colorectal cancer. That is why the test includes a protein biomarker (hemoglobin), 7 distinct DNA point mutation biomarkers (KRAS gene), and 2 different DNA methylation biomarkers (NDRG4 and BMP3). One additional DNA biomarker (beta actin gene) confirms that the appropriate amount of stool DNA is analyzed in each individual sample. This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform.

Innovation supports Cologuard’s scientific platform